Form 4 Filing for CRESCENT BIOPHARMA, INC.

Ellie Im, Chief Medical Officer of CRESCENT BIOPHARMA, INC., reported a sale of 1219 ordinary shares on June 22, 2026. The shares were sold at a weighted average price of $17.99, with individual transactions ranging from $16.88 to $18.86. This sale was conducted to cover tax withholding obligations related to the settlement of restricted stock units granted on December 15, 2025. The transactions were executed under a Rule 10b5-1 instruction adopted on February 25, 2026, specifically to manage tax liabilities upon the vesting of these units. Following the sale, Ellie Im owns 22,069 shares. The filing includes an undertaking to provide detailed information on the sale prices of individual transactions upon request.